Deal Announcements

Alder Biopharmaceuticals Secures $40 Million Funding

Monday, January 14, 2008 5:37:00 AM PDT | VentureDeal Staff

BOTHELL, WA -- Alder Biopharmaceuticals, Inc. announced that it has received $40 million in series C financing from a syndicate of venture capital investors.

Alder identifies, develops and manufactures antibody therapeutics focused on treating human autoimmune and inflammatory diseases.

Investors in the round were lead investors Delphi Ventures and TPG Biotech, and included Sevin Rosen Funds, Ventures West, H.I.G. Ventures and WRF Capital.

The company said it would use the funding proceeds to advance its lead candidate programs through the trials process and to continue development of its proprietary Mab Xpress yeast antibody production technology.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin

PCI - Level1